Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 24, No 22 (August 1), 2006: pp. 3570-3575
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.8866

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, P. M.
Right arrow Articles by Baxter, N. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, P. M.
Right arrow Articles by Baxter, N. N.
Related Articles
Right arrowRelated Correspondence

Increasing Negative Lymph Node Count Is Independently Associated With Improved Long-Term Survival in Stage IIIB and IIIC Colon Cancer

Paul M. Johnson, Geoff A. Porter, Rocco Ricciardi, Nancy N. Baxter

From the Department of Surgery, Dalhousie University, Halifax, Nova Scotia; Department of Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; Department of Surgery, University of Minnesota, Minneapolis, MN

Address reprint requests to Nancy Baxter, MD, PhD, Division of General Surgery, St Michael's Hospital, 30 Bond St, CC16-040, Toronto, Ontario, Canada, M5B 1W8; e-mail: baxtern{at}smh.toronto.on.ca

PURPOSE: The purpose of this study was to examine the impact of the number of negative lymph nodes on survival in patients with stage III colon cancer.

PATIENTS AND METHODS: Patients who underwent surgery for stage III colon cancer between January 1988 and December 1997 were identified from the Surveillance, Epidemiology and End Results cancer registry. The number of negative and positive nodes was determined for 20,702 eligible patients. Disease-specific survival was examined by substage according to the number of negative nodes identified. A proportional hazards model was constructed to determine the effect of the number of negative nodes on survival.

RESULTS: For stage IIIB and IIIC patients, there was a significant decrease in disease-specific mortality as the number of negative nodes increased; cumulative 5-year cancer mortality was 27% in stage IIIB patients with 13 or more negative nodes identified versus 45% in those with three or fewer negative lymph nodes evaluated (P < .0001). In patients with stage IIIC cancer, those with 13 or more negative nodes had a 5-year mortality of 42% versus 65% in those with three or fewer negative lymph nodes evaluated (P < .0001). There was no association between the number of negative nodes identified and disease-specific survival for patients with stage IIIA disease. After controlling for the number of positive nodes, a higher number of negative nodes was found to be independently associated with improved disease-specific survival.

CONCLUSION: The number of negative nodes is an important independent prognostic factor for patients with stage IIIB and IIIC colon cancer.

Supported by an American Society of Clinical Oncology career development award (N.N.B.).

Presented in part at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, January 26-28, 2006.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • Quality of Pathology Reporting Impacts on Lymph Node Yield in Colon Cancer
    Nicholas A. Rieger, Frances S. Barnett, James W.E. Moore, Sumitra S. Ananda, Matthew Croxford, Julie Johns, and Peter Gibbs
    JCO 2007 25: 463 [Full Text]


This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
S. L. Chen and A. J. Bilchik
Resecting Lymph Nodes in Colon Cancer: More than a Staging Operation?
Ann. Surg. Oncol., August 1, 2007; 14(8): 2175 - 2176.
[Full Text] [PDF]


Home page
JCOHome page
E. J. A. Morris, N. J. Maughan, D. Forman, and P. Quirke
Identifying Stage III Colorectal Cancer Patients: The Influence of the Patient, Surgeon, and Pathologist
J. Clin. Oncol., June 20, 2007; 25(18): 2573 - 2579.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. A. Rieger, F. S. Barnett, J. W.E. Moore, S. S. Ananda, M. Croxford, J. Johns, and P. Gibbs
Quality of Pathology Reporting Impacts on Lymph Node Yield in Colon Cancer
J. Clin. Oncol., February 1, 2007; 25(4): 463 - 463.
[Full Text] [PDF]


Home page
JCOHome page
N. N. Baxter
In Reply
J. Clin. Oncol., February 1, 2007; 25(4): 463 - 464.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online